Testing NEU-411 for early Parkinson's with LRRK2 gene change
Part of Brain & nervous system clinical trials.
This trial tests an experimental drug called NEU-411 for people with early Parkinson's disease who have a specific genetic change (LRRK2). It aims to see if the drug can slow the disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 80 years old
- You have been diagnosed with Parkinson's disease by a doctor
- You have a specific genetic change (LRRK2) that is found through a special test
- Your Parkinson's is at an early to moderate stage (you can walk and manage daily activities with some help)
- You do not have other conditions that might cause Parkinson's-like symptoms
- Your diabetes, if you have it, is well controlled
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment made from your own cells to replace damaged brain cells, aiming to improve movement and reduce symptoms. It's for people who have had Parkinson's for at least 4 years and respond well to levodopa.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This research study uses advanced MRI brain imaging to understand how a specific gene mutation (LRRK2) affects certain brain chemicals in people with Parkinson's disease. The goal is to learn more about how this genetic form of Parkinson's works, which could help develop better treatments.
This trial tests a new oral medicine, GT-02287, to see if it can help people with early Parkinson's disease. It aims to improve symptoms and slow the disease, and it also tracks how the medicine affects certain markers in the body.
This study tests an investigational drug called LBT-3627 to see if it is safe and how the body processes it. It includes healthy volunteers and people with Parkinson's disease, and may help determine if the drug could be a future treatment.
This study tests an investigational drug called LY4006896 in healthy people and in people with Parkinson's disease. It aims to see if the drug is safe and how it affects the body, which may help in developing a new treatment for Parkinson's.
Hear when a new Parkinson trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.